Edition:
United States

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

16.25USD
11 Dec 2017
Change (% chg)

$0.25 (+1.56%)
Prev Close
$16.00
Open
$16.05
Day's High
$16.30
Day's Low
$15.32
Volume
465,934
Avg. Vol
162,281
52-wk High
$17.70
52-wk Low
$9.30

Latest Key Developments (Source: Significant Developments)

Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals
Friday, 8 Dec 2017 11:33am EST 

Dec 8 (Reuters) - Sucampo Pharmaceuticals Inc ::LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING.  Full Article

Sucampo reports Q3 GAAP earnings per share $0.19
Wednesday, 1 Nov 2017 06:30am EDT 

Nov 1 (Reuters) - Sucampo Pharmaceuticals Inc :Sucampo reports third quarter 2017 financial results.Q3 GAAP earnings per share $0.19.Q3 revenue $61.3 million versus I/B/E/S view $58 million.Q3 earnings per share view $0.25 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $1.10 to $1.15.Q3 adjusted earnings per share $0.27.Sucampo Pharmaceuticals Inc - For FY17 ‍sucampo now expects total revenue of $250.0 million to $255.0 million​.Q3 earnings per share view $0.25, revenue view $58.0 million -- Thomson Reuters I/B/E/S.Sucampo Pharmaceuticals Inc - Sees FY 2017 ‍free cash flow of $99.0 million to $104.0 million​.Sucampo Pharmaceuticals - ‍Increases 2017 guidance for all key financial metrics based on "stronger than expected" sales of Amitiza in U.S. & Japan.FY2017 earnings per share view $1.01, revenue view $234.5 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo Pharmaceuticals announces FDA acceptance of sNDA for AMITIZA
Thursday, 28 Sep 2017 05:34pm EDT 

Sept 28 (Reuters) - Sucampo Pharmaceuticals Inc :Sucampo Pharmaceuticals announces FDA acceptance of sNDA for amitiza in children with pediatric functional constipation, with priority review designation.Sucampo Pharmaceuticals Inc - ‍FDA has assigned a user fee goal date of January 28, 2018.​.Sucampo Pharmaceuticals Inc - ‍filing has received priority review designation from FDA​.  Full Article

Cancer Prevention Pharmaceuticals receives $9.5 mln in additional funding from Sucampo
Monday, 11 Sep 2017 08:30am EDT 

Sept 11 (Reuters) - Sucampo Pharmaceuticals Inc ::Cancer Prevention Pharmaceuticals receives $9.5 million in additional funding from sucampo following phase 3 trial progress.‍cancer Prevention Pharmaceuticals - Sucampo paid CPP $4.5 million in option fees and invested $5.0 million in cpp via a convertible note​.‍cancer Prevention Pharmaceuticals - received total of $9.5 million from its North America commercialization partner Sucampo Pharmaceuticals Inc.​.  Full Article

Sucampo reports Q2 GAAP loss per share $3.92
Wednesday, 2 Aug 2017 06:30am EDT 

Aug 2 (Reuters) - Sucampo Pharmaceuticals Inc ::Sucampo reports second quarter 2017 financial results.Q2 GAAP loss per share $3.92.Q2 revenue $59.9 million versus i/b/e/s view $56.4 million.Sees FY 2017 adjusted earnings per share $1.00 to $1.10.Q2 adjusted earnings per share $0.28 excluding items.Sees FY 2017 revenue $220 million to $230 million.Q2 earnings per share view $0.27 -- Thomson Reuters I/B/E/S.Sucampo Pharmaceuticals Inc - company reiterates 2017 guidance.FY2017 earnings per share view $1.04, revenue view $233.6 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo Pharmaceuticals announces issuance of new patent for VTS-270
Tuesday, 13 Jun 2017 04:30pm EDT 

June 13 (Reuters) - Sucampo Pharmaceuticals Inc :Sucampo Pharmaceuticals announces issuance of new patent for VTS-270.Sucampo Pharmaceuticals Inc - U.S. Patent and trademark office has issued a patent for VTS-270.  Full Article

Sucampo Pharmaceuticals files for mixed shelf of up to $250 mln
Friday, 9 Jun 2017 04:57pm EDT 

June 9 (Reuters) - Sucampo Pharmaceuticals Inc :Sucampo Pharmaceuticals Inc files for mixed shelf of up to $250.0 million - SEC filing.  Full Article

Sucampo Pharmaceuticals files for offering of up to 2.8 mln shares of class A common stock by selling stockholders
Friday, 9 Jun 2017 04:46pm EDT 

June 9 (Reuters) - Sucampo Pharmaceuticals Inc ::Sucampo Pharmaceuticals Inc files for offering of up to 2.8 million shares of co's class a common stock by selling stockholders - sec filing.  Full Article

Sucampo Q1 gaap earnings per share $0.10
Wednesday, 3 May 2017 06:30am EDT 

May 3 (Reuters) - Sucampo Pharmaceuticals Inc ::Sucampo reports first quarter 2017 financial results.Q1 gaap earnings per share $0.10.Q1 revenue $56.3 million versus i/b/e/s view $54.1 million.Sees fy 2017 adjusted earnings per share $1.00 to $1.10.Q1 adjusted earnings per share $0.23.Sees fy 2017 revenue $220 million to $230 million.Q1 earnings per share view $0.27 -- Thomson Reuters I/B/E/S.Says company reiterates 2017 guidance.Fy2017 earnings per share view $1.09, revenue view $233.4 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo acquires Vtesse in a deal valued at $200 mln
Monday, 3 Apr 2017 06:30am EDT 

Sucampo Pharmaceuticals Inc : Sucampo Pharmaceuticals Inc- transaction valued at $200 million upfront . Sucampo acquires Vtesse Inc . Deal expected to be accretive to earnings beginning in 2019 . Sucampo Pharmaceuticals Inc- Vtesse employees are expected to join Sucampo . Sucampo pharmaceuticals - acquisition provides sucampo with vts-270, which is in a pivotal study for treatment of niemann-pick disease type c1 (npc-1) . Vtesse team will continue to support advancement of vts-270 . Sucampo Pharma -upfront payment made in form of issuance of 2.8 million Sucampo class a common shares to Vtesse shareholders and $170 million in cash on hand . Sucampo Pharmaceuticals Inc- revised full year 2017 guidance post Vtesse, revenue $220 million - $230 million . Sucampo pharmaceuticals inc- revised full year 2017 guidance post Vtesse for adjusted. Eps $1.00 - $1.10 . Sucampo Pharmaceuticals - Vtesse and Sucampo intend to establish a foundation after closing of acquisition to support research related to NPC disease .Sucampo Pharmaceuticals Inc says revised full year 2017 guidance guidance post Vtesse, free cash flow $86 million - $96 million.  Full Article

BRIEF-Linden Capital Reports A 5.1 Pct Passive Stake In Sucampo Pharmaceuticals

* LINDEN CAPITAL L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN SUCAMPO PHARMACEUTICALS INC AS OF DECEMBER 6, 2017 - SEC FILING Source text : [http://bit.ly/2jz2syj] Further company coverage: